Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224223 | 0.92 | TP53 (0.60) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL28991551 | 0.84 | KDM4E (0.67) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL28698891 | 0.84 | KDM4E (0.67) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL4012453 | 0.82 | KDM4E (0.65) | KDM4EHPGDLMNAKMT2AMEN1 | |
| SCHEMBL31498840 | 0.82 | KDM4E (0.65) | KDM4EHPGDLMNAKMT2AMEN1 | |
| SCHEMBL18413798 | 0.82 | TP53 (0.65) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL28115512 | 0.81 | KDM4E (0.63) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL8555545 | 0.81 | KDM4E (0.46) | KDM4EHPGDHSD17B10LMNATP53 | |
| SCHEMBL1859925 | 0.81 | POLB (0.64) | TP53KMT2AMEN1HDAC1HDAC6 | |
| SCHEMBL7004405 | 0.80 | HTR2A (0.73) | KDM4EHPGDHSD17B10LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613420-A1 | SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN | Newlink Genetics Corporation (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20110280806-A1 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2011-11-17 | — | — | US | disclosed |
| US-20110280806-A1 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2011-11-17 | — | — | US | disclosed |
| EP-2373349-A1 | DYE CONJUGATE IMAGING AGENTS | GE Healthcare AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010057944-A9 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010057944-A9 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010057944-A1 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057944-A1 | DYE CONJUGATE IMAGING AGENTS | GE HEALTHCARE AS (NO) | 2010-05-27 | — | — | WO | disclosed |
| US-5556874-A | ENZYME INHIBITORS AS ANTICARCINOGENIC AGENTS | WARNER LAMBERT COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| US-5464861-A | Anticarcinogenic agents | WARNER-LAMBERT (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0654024-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003427-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280806-A1 | DYE CONJUGATE IMAGING AGENTS | DSC1, SDCBP, DOCK5 | KDM4E 3469/4885HPGD 2178/4885HSD17B10 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.